June 30, 2018 : Issue #944

American Diabetes Association 78th Scientific Sessions Special Issue
This newsletter is Part 1 of our series on all the breaking news coming from the 78th Scientific Sessions of the American Diabetes Association 2018 in Orlando

• Watson Artificial Intelligence (AI) Helping People with Diabetes
• DURATION-8 Trial: Combining a GLP-1 Receptor Agonist Plus an SGLT-2 Inhibitor
• Adding an SGLT-2 Inhibitor For Type 1 Diabetes
• Sotagliflozin (SGLT-2) in Conjunction with Insulin for T1D Reduces Average Glucose Levels
• Six-Month Implantable Continuous Glucose Sensor Shows Accuracy In Type 1 Diabetes
• Accuracy Comparison of the Dexcom G5, Abbott Freestyle Libre Pro, and Senseonics Eversense
• Let’s Take a Closer Look at the New Dexcom G6
• A Two Hormone, Artificial Pancreas (DAP) Significantly Improves Glucose Levels

Steve, Joy, Kaytie, Kennon and Michelle are all back from the ADA 78th Scientific sessions. This turned out to be a great year to have our largest reporting staff ever. There were so many things to cover that I almost wish I had not been cycling in the hills of Western Virginia and could have been there.

I am sure many of you received daily updates from the ADA and other news sources, but we believe we will deliver the inside scoops that the others don’t get. We met with many of the abstract writers and our LECOM interns talked to multiple poster providers. Steve and Joy were able to record over 50 private interviews with key presenters and company officials that we will have for you over the next few weeks.

This week we start our coverage with technology and diabetes care, featuring articles on AI, CGMS and new delivery devices as well as information on a new dual purpose diabetes medication.

*****************************

We can make a difference!

*****************************

Dave Joffe

Editor-in-chief

6/21/18: The U.S. FDA has approved the t:slim X2™Insulin Pump with Basal-IQ™technology, a predictive low glucose suspend (PLGS) feature designed to help reduce the frequency and duration of low glucose events (hypoglycemia). This is the first automated insulin delivery system approved for use by children as young as 6 years old, and the first insulin pump designated as compatible with integrated continuous glucose monitoring (iCGM) devices. — https://www.businesswire.com/news/home/20180621006260/en/Tandem-Diabetes-Care-Announces-FDA-Approval-tslim

6/21/18: The U.S. FDA has approved the Eversense Continuous Glucose Monitoring system for use in people 18 years of age and older with diabetes. The system includes a fully implantable sensor to detect glucose, which can be worn for up to 90 days. — https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm611454.htm

6/21/18: The U.S. FDA has expanded the approval of the MiniMed 670G hybrid closed-looped system, a diabetes management device that is intended to automatically monitor glucose and provide appropriate basal insulin doses with little or no input from the user, to include individuals ages 7 to 13 with T1D — https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm611475.htm

Do you recommend a CGM for all your patients who are not achieving their target blood glucose and who are on insulin? Follow the link to respond.

The implantable CGM was one of the hottest new products at the ADA meeting. Senseonics is the first and only CGM system to feature an implantable glucose sensor and provide long-term continuous monitoring for up to three months. Eversense is for people who want to actively manage their diabetes simply and confidently. It provides continuous glucose monitoring for up to 3 months via a professionally inserted sensor, a removable and rechargeable smart transmitter with on-body vibe alerts, and a convenient smartphone app. Unlike ordinary CGM systems, Eversense provides complete freedom from weekly sensor insertions and site maintenance. See Article 5.

Mr. Huang manages his diabetes with his lifestyle modifications, metformin, and linagliptin, and returns every 6 months for follow-up visits. Three years after initiating this treatment plan, he returns to your clinic for his 6-month check-up. When asked how his diabetes management is going at home, he shares that recently he has been “unable to really get out and get as much exercise as he knows he should due to his creaky, old knees acting up.” His current office A1C is 8.8%. You discuss with him what the next management steps may be to achieve his individualized glycemic goal. What would your next medical management step be?

A. Add a rapid-acting insulin analogue
B. Add a long-acting insulin analogue
C. Add a GLP-1 agonist
D. Add a sulfonylurea
Follow the link for the answer.

New mobile app from Medtronic, Sugar.IQ™, applies AI technology from IBM Watson Health to help people with diabetes make more informed decisions.

With over 6 million possible combinations, it is difficult to come up with the best treatment for each patient. The phase III DURATION-8 trial may help you to decide.

DEPICT-2 study of more than 800 people worldwide indicates positive results without added risk of severe hypoglycemia, but slight increase in DKA events.

One-year results of North American inTandem1 study show decreased HbA1c levels and lower risk of severe hypoglycemia.

The FDA approved the 90-day version of the implantable CGM Sensor.

For those who use insulin, accuracy is one of the most important things to consider when using a CGM.

“Simple,” “Accurate,” and “Effective” were the words ADA presenters used to describe Dexcom G6, a new continuous glucose monitor (CGM) system.

A dual-hormone, artificial pancreas delivering rapid insulin and the drug pramlintide improved glucose management and reduced glucose variability in adults with type 1 compared to an insulin-only, first-generation artificial pancreas.

Quote of the Week!

“Every day brings new choices.”

…Martha Beck

Diabetes in Control gratefully acknowledges the assistance of the following pharmacy doctoral candidates in the preparation of this week’s newsletter:

Kaytie A. Weierstahl, Pharm.D. Candidate, LECOM School of Pharmacy

Kennen Munoz Munoz, Pharm. D. Candidate 2019, LECOM School of Pharmacy

Your Friends in Diabetes Care
Steve and Dave
Diabetes In Control
810 Bear Tavern Road Suite 102
Ewing, NJ, 08628
USA
www.diabetesincontrol.com